α2A-AR CRISPR Activation Plasmid (m): sc-419023-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- α2A-AR CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- α2A-AR CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by α2A-AR CRISPR Activation Plasmid (m) and α2A-AR CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Adra2a transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
α2A-AR CRISPR Activation Plasmid (m) | sc-419023-ACT | 20 µg | $397.00 |
Adra2a encodes the mouse alpha2A-AR, a Gi/o-coupled adrenergic receptor that mediates inhibitory signaling in response to norepinephrine and epinephrine. Receptor activation suppresses adenylyl cyclase activity to reduce cAMP/PKA signaling, modulates ion channel conductance, and influences downstream MAPK and phospholipase pathways that shape synaptic transmission and cellular excitability. In the central and peripheral nervous systems, alpha2A-AR regulates neurotransmitter release and autonomic tone, with additional roles in vascular and metabolic regulation. Dysregulated adrenergic signaling involving ADRA2A has been linked to neuropsychiatric phenotypes, stress-response circuitry, pain processing, and cardiometabolic traits, supporting its use in mechanistic pathway studies.
α2A-AR CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Adra2a expression without altering the underlying DNA sequence.
α2A-AR CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Adra2a locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Adra2a transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous α2A-AR expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Adra2a locus and enabling the study of α2A-AR-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of α2A-AR pathway restoration in tumor cells with silenced or reduced Adra2a expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.